Your session is about to expire
← Back to Search
Psilocybin + MBSR for Burnout (PAPR Trial)
Phase < 1
Recruiting
Research Sponsored by University of Utah
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up study enrollment to 2 weeks and 6 months post intervention
Awards & highlights
No Placebo-Only Group
Summary
This trial will study the efficacy of MBSR + psilocybin psychotherapy for frontline healthcare workers battling depression & burnout from the pandemic.
Who is the study for?
This trial is for frontline healthcare providers (physicians or nurses) who have at least one month of experience during the COVID pandemic and are experiencing depression and burnout. They must not be on medication for depression/anxiety, should have a support person post-psilocybin session, agree to avoid psychoactive drugs before sessions, and meet specific health criteria including liver function tests.
What is being tested?
The study compares an 8-week Mindfulness-Based Stress Reduction (MBSR) program with the same MBSR program plus a group psilocybin-assisted psychotherapy intervention. It includes preparatory sessions, one psilocybin administration session with individual therapist attention, and integration sessions afterwards.
What are the potential side effects?
Possible side effects from psilocybin may include changes in sense perception, altered thinking processes, anxiety, headache or dizziness. Mindfulness practice typically has minimal risks but can sometimes cause discomfort when confronting difficult emotions.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ study enrollment to 2 weeks and 6 months post intervention
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~study enrollment to 2 weeks and 6 months post intervention
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Mental Depression
Secondary study objectives
Phosphorus
Phosphorus
Personality inventories
+4 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Mindfulness-Based Stress Reduction (MBSR) + Psilocybin-Assisted Psychotherapy (PAP)Experimental Treatment2 Interventions
Participants in the MBSR + PAP arm will complete an 8-week Mindfulness-Based Stress Reduction Curriculum involving a weekly 2 hour group meeting (either in person or virtual). They will additionally complete a psilocybin-assisted psychotherapy (PAP) intervention that involves three 2-hour group preparatory sessions, a single 8-hour group psilocybin administration session (done in place of the mindfulness retreat), and three 2-hour group integration sessions. All PAP intervention sessions will utilize a 1:1 therapist to participant ratio with an additional lead therapist present.
Group II: Mindfulness-Based Stress Reduction (MBSR)Active Control1 Intervention
Participants in the MBSR arm will complete an 8-week Mindfulness-Based Stress Reduction Curriculum involving a weekly 2 hour group meeting (either in person or virtual) as well as a 8 hour group mindfulness retreat in week 6-7 of the curriculum.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Psilocybin
2021
Completed Phase 2
~750
Mindfulness-Based Stress Reduction (MBSR)
2018
Completed Phase 2
~1430
Find a Location
Who is running the clinical trial?
Heffter Research InstituteOTHER
13 Previous Clinical Trials
475 Total Patients Enrolled
3 Trials studying Depression
104 Patients Enrolled for Depression
University of UtahLead Sponsor
1,134 Previous Clinical Trials
1,791,092 Total Patients Enrolled
23 Trials studying Depression
2,381 Patients Enrolled for Depression
Usona InstituteOTHER
15 Previous Clinical Trials
953 Total Patients Enrolled
9 Trials studying Depression
769 Patients Enrolled for Depression
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- Your liver enzymes should be less than three times the normal limit at the medical center where you are being treated.You currently have a specific type of personality disorder according to a doctor's evaluation.You have had thoughts about hurting yourself in the past month, as determined by certain questions on a specific rating scale.You have a medical condition that is not well controlled, like heart problems, kidney issues, or liver disorders. Your doctor thinks it's not safe for you to join the study or follow study rules because of other health concerns.You or your close family members have a history of certain mental health conditions like schizophrenia or bipolar disorder.You have a mental health condition that might make it unsafe for you to take psilocybin, as determined by your own report and medical records.You have severe depression that needs to be treated right away with standard care, like being in the hospital.You have a PHQ-9 score of 10 or higher and are diagnosed with a depressive disorder according to the DSM-5.Your liver is working well, as shown by blood tests for bilirubin and liver enzymes.You are able to perform everyday activities without help or needing to stay in bed most of the time.You have had a problem with drugs or alcohol within the last two years, as determined by a urine test and medical records.You have high scores on the emotional exhaustion and depersonalization or personal accomplishment tests, indicating burnout.You have not been taking prescribed medications for depression and anxiety for at least 4 weeks before the study starts.You have cancer that has spread to your brain, or you have had previous treatment for cancer that has spread to your brain, or you have a major disease affecting your central nervous system.If you need to use opioid pain medications, you must have taken your last dose at least 6 hours before receiving the psilocybin treatment, and you cannot take another dose until at least 6 hours after the treatment.
Research Study Groups:
This trial has the following groups:- Group 1: Mindfulness-Based Stress Reduction (MBSR)
- Group 2: Mindfulness-Based Stress Reduction (MBSR) + Psilocybin-Assisted Psychotherapy (PAP)
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Depression Patient Testimony for trial: Trial Name: NCT05557643 — Phase < 1
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger